Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Human medicine
Name of medicinal product: PALFORZIA
Active substances:
peanut protein
Estonian, English, Latin
ATC code: V01AA86
Dosage form: oral powder in single-dose container
Strength: 20mg
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):
Package information leaflet (PIL): EST
Indication: PALFORZIA is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. PALFORZIA may be continued in patients 18 years of age and older. PALFORZIA should be used in conjunction with a peanut-avoidant diet.
Safety features: No
: This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Patients and healthcare professionals are asked to report any suspected adverse reactions to State Agency of Medicines.State Agency of Medicines
Marketing authorization holder: Aimmune Therapeutics Ireland Limited 
Marketing authorization number: EU/1/20/1495 
Marketing authorization issued on: December 17, 2020 
Marketing authorization expires on: December 21, 2025 
Marketing authorization procedure type: Centralised 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1836929  PALFORZIA  oral powder in single-dose container  20mg 16TK  Prescription           
1836930  PALFORZIA  oral powder in single-dose container  20mg 32TK  Prescription           
1836941  PALFORZIA  oral powder in single-dose container  20mg 64TK  Prescription           
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere